To examine whether tumor-infiltrating Vδ2− γδ T cells might be relevant in PD-1 blockade in another disease, we interrogated the tumor expression data in 168 samples from the IMvigor210 bladder cancer trial NCT02108652 (ref. 44) with our Vδ2− gene signature. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.